1. Scrip
  2. >>Archive

Pulling iclaprim out of the ashes

 
• By Sukaina Virji

Seven years ago, the antibiotic iclaprim looked dead in the water. Seven months ago, Motif Bio was barely a blip on the biotech radar. But seven years is a long time in the antibiotic space, and seven months is a long time in biotech. Things are looking very different for both iclaprim and Motif. Scrip met with CEO Graham Lumsden, formerly of Merck & Co, and chairman Richard Morgan, CEO of majority shareholder Amphion Innovations, to get the details.

Seven years ago, the antibiotic iclaprim looked dead in the water. Seven months ago, Motif Bio was barely a blip on the biotech radar. But seven years is a long time in the antibiotic space, and seven months is a long time in biotech. Things are looking very different for both iclaprim and Motif. Scrip met with CEO Graham Lumsden, formerly of Merck & Co, and chairman Richard Morgan, CEO of majority shareholder Amphion Innovations, to get the details.

'perfect storm'

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties

 
• By Sarah Karlin-Smith and Mandy Jackson

Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.